Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia

Clin Transl Sci. 2024;17:e70074.
Vaddady P, Glatard A, Smania G, Nakayama S, Inoue H, Kurumaddali A, Abutarif M, Zheng M.
JournalOncologyPharmacometricsRegulatory interactions

Pharmetheus Affiliates

Portrait-of-Giovanni-Smania_Pharmetheus-1
Principal Director, MIDD Consultant

Giovanni Smania

See bio
Portrait-of-Anais-Glatard_Pharmetheus
Senior Director, MIDD Consultant

Anaïs Glatard

See bio
Portrait-of-Christina-Pentafragka_Pharmetheus
Director, Quality Control & Medical Writing Consultant

Christina Pentafragka

See bio

Connected publication